文献速递泌尿男性生殖肿瘤

联合检测尿液中TMPRSS2:ERG与PCA3 RNA与侵袭性前列腺癌检出之间的关系

Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
PubMed 文献 · JAMA Oncol · 2017-01-01

这项前瞻性多中心诊断评估与验证研究纳入首次前列腺活检男性,评估直肠指检后尿液中PCA3与TMPRSS2:ERG RNA联合检测在检出Gleason评分≥7前列腺癌时能否提高特异性。开发队列516人特异性从18%升至39%,验证队列561人从17%升至33%(单侧95%CI下限0.73%,预设单侧P=0.04),敏感性93%得以保持。

要点

  • 联合尿液T2:ERG与PCA3检测在保持95%敏感性前提下,开发队列特异性由18%升至39%。
  • 验证队列确认特异性由17%升至33%,侵袭性前列腺癌检出敏感性保持93%。
  • 使用尿液检测结果筛选活检人群可避免42%的不必要前列腺活检。

核心结论

  • 联合尿液检测T2:ERG与PCA3可避免不必要的活检,同时保持检出侵袭性前列腺癌的稳健敏感性,并可能节省医疗费用。

研究设计与样本

  • 前瞻性、多中心诊断评估与验证研究,在学术及社区门诊泌尿外科诊所开展。
  • 开发队列748名前瞻性队列参与者中516名符合条件,验证队列928名中561名符合条件,均为首次前列腺活检且无既往前列腺癌的转诊男性。
  • 活检前行尿液PCA3与T2:ERG RNA检测,病理检测对尿液检测结果设盲。
  • 开发队列构建多重决策算法以优化特异性并维持95%敏感性,验证队列按预设分析、遵循PRoBE标准设盲验证。

主要发现

  • 开发队列516名男性(平均年龄62岁,范围33-85岁)中,联合检测在保持95%敏感性的阈值下将特异性从18%提高到39%。
  • 验证队列561名男性(平均年龄62岁,范围27-86岁)中,特异性从17%提高到33%(单侧95%CI下限0.73%,预设单侧P=0.04),侵袭性前列腺癌检出敏感性保持93%。
  • 使用尿液检测结果筛选活检人群可避免42%的不必要前列腺活检。
  • 成本分析提示该尿液检测算法限制前列腺活检在较年轻男性中具有更大潜在成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Potential survival benefits from treating aggressive (Gleason score, ≥7) early-stage prostate cancer are undermined by harms from unnecessary prostate biopsy and overdiagnosis of indolent disease. OBJECTIVE: To evaluate the a priori primary hypothesis that combined measurement of PCA3 and TMPRSS2:ERG (T2:ERG) RNA in the urine after digital rectal examination would improve specificity over measurement of prostate-specific antigen alone for detecting cancer with Gleason score of 7 or higher. As a secondary objective, to evaluate the potential effect of such urine RNA testing on health care costs. DESIGN, SETTING, AND PARTICIPANTS: Prospective, multicenter diagnostic evaluation and validation in academic and community-based ambulatory urology clinics. Participants were a referred sample of men presenting for first-time prostate biopsy without preexisting prostate cancer: 516 eligible participants from among 748 prospective cohort participants in the developmental cohort and 561 eligible participants from 928 in the validation cohort. INTERVENTIONS/EXPOSURES: Urinary PCA3 and T2:ERG RNA measurement before prostate biopsy. MAIN OUTCOMES AND MEASURES: Presence of prostate cancer having Gleason score of 7 or higher on prostate biopsy. Pathology testing was blinded to urine assay results. In the developmental cohort, a multiplex decision algorithm was constructed using urine RNA assays to optimize specificity while maintaining 95% sensitivity for predicting aggressive prostate cancer at initial biopsy. Findings were validated in a separate multicenter cohort via prespecified analysis, blinded per prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) criteria. Cost effects of the urinary testing strategy were evaluated by modeling observed biopsy results and previously reported treatment outcomes. RESULTS: Among the 516 men in the developmental cohort (mean age, 62 years; range, 33-85 years) combining testing of urinary T2:ERG and PCA3 at thresholds that preserved 95% sensitivity for detecting aggressive prostate cancer improved specificity from 18% to 39%. Among the 561 men in the validation cohort (mean age, 62 years; range, 27-86 years), analysis confirmed improvement in specificity (from 17% to 33%; lower bound of 1-sided 95% CI, 0.73%; prespecified 1-sided P = .04), while high sensitivity (93%) was preserved for aggressive prostate cancer detection. Forty-two percent of unnecessary prostate biopsies would have been averted by using the urine assay results to select men for biopsy. Cost analysis suggested that this urinary testing algorithm to restrict prostate biopsy has greater potential cost-benefit in younger men. CONCLUSIONS AND RELEVANCE: Combined urinary testing for T2:ERG and PCA3 can avert unnecessary biopsy while retaining robust sensitivity for detecting aggressive prostate cancer with consequent potential health care cost savings.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Sanda MG, Feng Z, Howard DH, et al. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncol. 2017. PMID: 28520829. doi:10.1001/jamaoncol.2017.0177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。